{"id":"pegylated-ifn-alpha-2b","safety":{"commonSideEffects":[{"rate":"70-90","effect":"Flu-like symptoms (fever, chills, fatigue)"},{"rate":"50-70","effect":"Headache"},{"rate":"40-60","effect":"Myalgia"},{"rate":"20-40","effect":"Depression"},{"rate":"10-30","effect":"Thrombocytopenia"},{"rate":"10-25","effect":"Neutropenia"},{"rate":"5-15","effect":"Thyroid dysfunction"}]},"_chembl":{"chemblId":"CHEMBL4650504","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Interferon-alpha 2b is a cytokine that binds to type I interferon receptors on cell surfaces, triggering JAK-STAT signaling pathways that upregulate antiviral genes and promote apoptosis in infected or malignant cells. Pegylation extends the drug's half-life by conjugating polyethylene glycol, allowing for less frequent dosing while maintaining therapeutic efficacy. This formulation is used primarily in chronic viral infections and certain malignancies.","oneSentence":"Pegylated interferon-alpha 2b activates innate immune responses by binding to interferon-alpha receptors, enhancing antiviral and antiproliferative activity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:23:12.415Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C"},{"name":"Chronic hepatitis B"},{"name":"Melanoma"},{"name":"Follicular lymphoma"}]},"trialDetails":[{"nctId":"NCT01935089","phase":"PHASE2","title":"Pilot Peg-Interferon-a2b in Decreasing Viral DNA in HIV","status":"COMPLETED","sponsor":"The Wistar Institute","startDate":"2013-08-07","conditions":"HIV-1 Infection","enrollment":20},{"nctId":"NCT00134030","phase":"PHASE3","title":"Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2005-11-14","conditions":"Localized Osteosarcoma, Metastatic Osteosarcoma","enrollment":1334},{"nctId":"NCT03117816","phase":"PHASE3","title":"ENDURE - Efficacy and Safety of AOP2014 With CML Patients in Remission","status":"COMPLETED","sponsor":"Philipps University Marburg","startDate":"2017-05-04","conditions":"Chronic Myeloid Leukemia in Remission","enrollment":214},{"nctId":"NCT05451420","phase":"NA","title":"Inactive HBsAg Carriers (IHCs) Treated With Pegylated Interferon α2b Based Intervention Therapy","status":"COMPLETED","sponsor":"Henan Provincial People's Hospital","startDate":"2017-12-01","conditions":"Chronic Hepatitis B","enrollment":33},{"nctId":"NCT03483987","phase":"NA","title":"Re-treatment of HCV Following DAA Failure","status":"TERMINATED","sponsor":"Sanjay Gandhi Postgraduate Institute of Medical Sciences","startDate":"2018-02-10","conditions":"Chronic Hepatitis C","enrollment":18},{"nctId":"NCT01387763","phase":"PHASE3","title":"A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms","status":"COMPLETED","sponsor":"Thomas Stauffer Larsen","startDate":"2012-01","conditions":"Polycythemia Vera, Essential Thrombocythemia, Primary Myelofibrosis","enrollment":202},{"nctId":"NCT03588715","phase":"PHASE1","title":"Peg-Interferon Alpha 2b Combined With Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074 (BEAT-2)","status":"UNKNOWN","sponsor":"Luis Montaner","startDate":"2020-06-18","conditions":"HIV, HIV/AIDS, HIV-1 Infection","enrollment":15},{"nctId":"NCT00525031","phase":"PHASE2","title":"Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-08","conditions":"Melanoma","enrollment":55},{"nctId":"NCT02447887","phase":"PHASE1, PHASE2","title":"Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC)","status":"TERMINATED","sponsor":"Fox Chase Cancer Center","startDate":"2015-08-14","conditions":"Metastatic Renal Cell Carcinoma, RCC","enrollment":3},{"nctId":"NCT01928511","phase":"PHASE4","title":"Efficacy of Switching or Adding Pegylated Interferon in Chronic Hepatitis B Patients on Long Term Oral Antiviral Therapy","status":"COMPLETED","sponsor":"Seng Gee Lim","startDate":"2014-01","conditions":"Chronic Hepatitis B","enrollment":254},{"nctId":"NCT01295515","phase":"PHASE1, PHASE2","title":"Interferon Alpha 2b Intensification in HIV-Positive Individuals on Antiretroviral Therapy","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-02-11","conditions":"HIV Infection","enrollment":7},{"nctId":"NCT01193699","phase":"PHASE1, PHASE2","title":"Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera","status":"COMPLETED","sponsor":"AOP Orphan Pharmaceuticals AG","startDate":"2010-08","conditions":"Polycythemia Vera","enrollment":24},{"nctId":"NCT01725204","phase":"PHASE2","title":"Safety and Efficacy of Pegylated IFN-alpha 2B Added to Dasatinib in Newly Diagnosed Chronic Phase Myeloid Leukemia","status":"COMPLETED","sponsor":"Norwegian University of Science and Technology","startDate":"2012-09","conditions":"Leukemia, Myeloid, Chronic-Phase","enrollment":40},{"nctId":"NCT02099604","phase":"PHASE3","title":"Efficacy and Safety of the Combination Vitamin D With Standard of Care in Egyptian Patients With Untreated Chronic Hepatitis C","status":"WITHDRAWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2014-04","conditions":"Chronic Hepatitis C","enrollment":""},{"nctId":"NCT00277238","phase":"PHASE2","title":"CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Non-Responder (Null And Partial Responder) Hepatitis C Virus (HCV) Genotype 1 Infected Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-02","conditions":"Hepatitis, Chronic Active","enrollment":113},{"nctId":"NCT00209209","phase":"PHASE3","title":"Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL","status":"UNKNOWN","sponsor":"European Mantle Cell Lymphoma Network","startDate":"2004-01-14","conditions":"Lymphoma, Mantle-Cell","enrollment":570},{"nctId":"NCT01949805","phase":"PHASE3","title":"Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera","status":"COMPLETED","sponsor":"AOP Orphan Pharmaceuticals AG","startDate":"2013-09","conditions":"Polycythemia Vera","enrollment":257},{"nctId":"NCT00856024","phase":"","title":"ATHENAS - Retrospective Study of Compliance in Chronic Hepatitis C With Pegylated Interferon Alfa-2b/Ribavirin in Brazil (P05632)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-07","conditions":"Hepatitis C, Chronic","enrollment":902},{"nctId":"NCT01529073","phase":"PHASE2","title":"Efficacy of Pegylated Interferon Plus Ribavirin Plus Nitazoxanide in HCV Genotype 4 and HIV Coinfection","status":"UNKNOWN","sponsor":"Juan Macías","startDate":"2012-02","conditions":"HCV Coinfection, HIV Infection","enrollment":45},{"nctId":"NCT00701298","phase":"PHASE1","title":"Decitabine With or Without Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Solid Tumors","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-04","conditions":"Unspecified Adult Solid Tumor, Protocol Specific","enrollment":30},{"nctId":"NCT01639885","phase":"PHASE1, PHASE2","title":"Chemo-immunotherapy (Gemcitabine, Interferon-alpha 2b and p53 SLP) in Patients With Platinum-resistant Ovarian Cancer","status":"COMPLETED","sponsor":"Leiden University Medical Center","startDate":"2011-08","conditions":"Recurrent Ovarian Cancer","enrollment":15},{"nctId":"NCT00621439","phase":"NA","title":"Investigative Trial of Interferon Alpha-2b To Shrink Cancer of the Eye","status":"WITHDRAWN","sponsor":"Emory University","startDate":"2007-03","conditions":"Ocular Melanoma","enrollment":""},{"nctId":"NCT01374308","phase":"PHASE3","title":"NASVAC Phase-III Trial in Chronic Hepatitis B (CHB) Patients","status":"UNKNOWN","sponsor":"Clinical Research Organization, Dhaka, Bangladesh","startDate":"2011-06","conditions":"Chronic Hepatitis B","enrollment":160},{"nctId":"NCT00502099","phase":"PHASE4","title":"Comparison of Pegasys Versus Peg-Intron for Treatment of Chronic Hepatitis C Genotype 4","status":"COMPLETED","sponsor":"Amr Hafez","startDate":"2006-01","conditions":"Hepatitis C","enrollment":217},{"nctId":"NCT00593151","phase":"PHASE1, PHASE2","title":"Study of Safety, Tolerability, and Anti-Viral Effect of Locteron Compared to PEG-Intron in Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Biolex Therapeutics, Inc.","startDate":"2008-01","conditions":"Hepatitis C","enrollment":32},{"nctId":"NCT00863239","phase":"PHASE2","title":"Phase 2B Dose Ranging Study of Locteron Plus Ribavirin to Treat HCV","status":"COMPLETED","sponsor":"Biolex Therapeutics, Inc.","startDate":"2009-03","conditions":"Hepatitis C, Chronic","enrollment":116},{"nctId":"NCT00746746","phase":"PHASE2","title":"A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma","status":"UNKNOWN","sponsor":"Ochsner Health System","startDate":"2008-06","conditions":"Melanoma","enrollment":30},{"nctId":"NCT00084279","phase":"PHASE2","title":"CIFN and IFN γ-1b With or Without Ribavirin for Treatment of Chronic Hepatitis C (Nonresponders)","status":"COMPLETED","sponsor":"InterMune","startDate":"2004-04","conditions":"Chronic Hepatitis C","enrollment":81},{"nctId":"NCT00277862","phase":"PHASE4","title":"Pegylated Interferon and Ribavirin Therapy in Chronic Hepatitis Genotype 4","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2002-04","conditions":"Hepatitis C","enrollment":280},{"nctId":"NCT00088504","phase":"PHASE2","title":"Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis C","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2004-07","conditions":"Hepatitis C, Hepatitis","enrollment":315}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":56,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["PEG-IFN alpha-2b","PEG-Intron™"],"phase":"marketed","status":"active","brandName":"Pegylated IFN- alpha 2b","genericName":"Pegylated IFN- alpha 2b","companyName":"Ain Shams University","companyId":"ain-shams-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pegylated interferon-alpha 2b activates innate immune responses by binding to interferon-alpha receptors on immune cells, enhancing antiviral and anti-tumor activity. Used for Chronic hepatitis C, Chronic hepatitis B, Melanoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}